LeMaitre Vascular, Inc. $LMAT Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 149,788 shares of the medical instruments supplier’s stock after selling 23,748 shares during the period. JPMorgan Chase & Co.’s holdings in LeMaitre Vascular were worth $12,440,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Annex Advisory Services LLC lifted its holdings in LeMaitre Vascular by 535.2% during the 2nd quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier’s stock worth $18,243,000 after buying an additional 185,085 shares in the last quarter. Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after acquiring an additional 115,141 shares in the last quarter. Invesco Ltd. raised its stake in shares of LeMaitre Vascular by 34.5% in the first quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier’s stock valued at $19,753,000 after acquiring an additional 60,438 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares during the period. Finally, Nuveen LLC acquired a new position in LeMaitre Vascular during the 1st quarter worth $4,631,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 1.4%

LMAT stock opened at $84.53 on Monday. The stock has a market cap of $1.92 billion, a P/E ratio of 36.44, a PEG ratio of 2.09 and a beta of 0.68. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $105.55. The company’s 50 day moving average is $86.88 and its two-hundred day moving average is $87.11.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. During the same quarter in the prior year, the business posted $0.49 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of LeMaitre Vascular in a report on Tuesday, December 2nd. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Barrington Research reissued an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.20.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.